SNGX

Soligenix Inc

Add to Watchlist

Advanced Chart

3.290

+0.09(2.812%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

3.750

Open

3.220

VWAP

3.61

Vol

2.17M

Mkt Cap

10.74M

Low

3.220

Amount

7.81M

EV/EBITDA(TTM)

Total Shares

987.49K

3.15M

EV/OCF(TTM)

P/S(TTM)

3.08K

Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q1

0.00

-100%

Estimates Revision

The market is revising No Change the revenue expectations for Soligenix, Inc. (SNGX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 67.01%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+67.01%

In Past 3 Month

1 Analyst Rating

82.37% Upside

Wall Street analysts forecast SNGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNGX is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

82.37% Upside

Current: 3.290

Low

6.00

Averages

6.00

High

6.00

82.37% Upside

Current: 3.290

Low

6.00

Averages

6.00

High

6.00

Alliance Global Partners

James Molloy

Buy

downgrade

$10 -> $6

2025-07-16

Reason

Alliance Global Partners

James Molloy

Price Target

$10 -> $6

2025-07-16

downgrade

Buy

Reason

Alliance Global Partners analyst James Molloy lowered the firm's price target on Soligenix to $6 from $10 and keeps a Buy rating on the shares after the company reported recent corporate updates and clinical progress of HyBryte. The firm says its price target represents a sum-of-the-parts.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Soligenix Inc (SNGX.O) is -1.12, compared to its 5-year average forward P/E of -2.11. For a more detailed relative valuation and DCF analysis to assess Soligenix Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.11

Current PE

-1.12

Overvalued PE

-0.33

Undervalued PE

-3.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Overvalued

5Y Average PS

17.92

Current PS

81.22

Overvalued PS

33.58

Undervalued PS

2.26